161 related articles for article (PubMed ID: 11137652)
1. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study.
Thakur CP
Int J Antimicrob Agents; 2001 Jan; 17(1):67-70. PubMed ID: 11137652
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.
Thakur CP; Pandey AK; Sinha GP; Roy S; Behbehani K; Olliaro P
Trans R Soc Trop Med Hyg; 1996; 90(3):319-22. PubMed ID: 8758093
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
[TBL] [Abstract][Full Text] [Related]
4. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
5. Costs of amphotericin B lipid complex for kala-azar.
Basnyat B
Ann Intern Med; 1998 Feb; 128(4):326. PubMed ID: 9471948
[No Abstract] [Full Text] [Related]
6. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
Sundar S; Agrawal G; Rai M; Makharia MK; Murray HW
BMJ; 2001 Aug; 323(7310):419-22. PubMed ID: 11520836
[TBL] [Abstract][Full Text] [Related]
8. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
[TBL] [Abstract][Full Text] [Related]
9. Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India.
Thakur CP; Ahmed S
Indian J Med Res; 2001 Jan; 113():14-8. PubMed ID: 11280166
[TBL] [Abstract][Full Text] [Related]
10. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
12. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VR; Buffels R
Am J Trop Med Hyg; 2002 Feb; 66(2):143-6. PubMed ID: 12135284
[TBL] [Abstract][Full Text] [Related]
13. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Meyerhoff A
Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
[TBL] [Abstract][Full Text] [Related]
14. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis.
Sundar S; Gupta LB; Rastogi V; Agrawal G; Murray HW
Trans R Soc Trop Med Hyg; 2000; 94(2):200-4. PubMed ID: 10897369
[TBL] [Abstract][Full Text] [Related]
15. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.
Khalil EA; Weldegebreal T; Younis BM; Omollo R; Musa AM; Hailu W; Abuzaid AA; Dorlo TP; Hurissa Z; Yifru S; Haleke W; Smith PG; Ellis S; Balasegaram M; EL-Hassan AM; Schoone GJ; Wasunna M; Kimutai R; Edwards T; Hailu A
PLoS Negl Trop Dis; 2014; 8(1):e2613. PubMed ID: 24454970
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparison of classical mode of administration of amphotericin B with its newer modes of administration in kala-azar.
Thakur CP; Kumar P; Kumar N; Singh GN; Singh AK; Narain S
J Assoc Physicians India; 1998 Sep; 46(9):779-83. PubMed ID: 11229246
[TBL] [Abstract][Full Text] [Related]
18. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion.
Berman J; Dietze R
Chemotherapy; 1999 Jun; 45 Suppl 1():54-66. PubMed ID: 10394022
[TBL] [Abstract][Full Text] [Related]
19. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
20. Ambisome plus miltefosine for Indian patients with kala-azar.
Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
